Grifols (GIFLF) Other Operating Expenses (2010 - 2020)
Grifols (GIFLF) reported Other Operating Expenses of -$74.9 million for Q1 2020, down 5.28% on a YoY basis from -$79.1 million in Q2 2019, and up 66.32% quarter-over-quarter from -$222.5 million in Q4 2019.
Grifols (GIFLF) Other Operating Expenses (2010 - 2020) Analysis & Trends
Grifols has reported Other Operating Expenses for 9 years, with the latest figure at -$74.9 million in Q1 2020.
- For the quarter ending Q1 2020, Other Operating Expenses fell 5.28% year-over-year to -$74.9 million; the trailing twelve-month figure through Dec 2021 stood at -$74.9 million (up 74.81% YoY), and the FY2025 full-year result was -$0.0, changed N/A from the prior year.
- Other Operating Expenses for Q1 2020 stood at -$74.9 million, up from -$222.5 million in the prior quarter.
- The five-year high for Other Operating Expenses was $0.0 in Q3 2016, with the low at -$222.5 million in Q4 2019.
- Historically, Other Operating Expenses has averaged -$100.7 million across 5 years, with a median of -$71.2 million in 2019.
- Annual changes were most pronounced in 2017 — Other Operating Expenses tumbled 8.982359418921494e+16% — and 2018, when it grew 9.14%.
- Grifols' Other Operating Expenses stood at -$0.0 in 2016, then plunged by 8.982359418921494e+16% to -$214.2 million in 2017, then advanced by 9.14% to -$194.6 million in 2018, then slipped by 14.33% to -$222.5 million in 2019, then surged by 66.32% to -$74.9 million in 2020.
- The last three Other Operating Expenses figures came in at -$74.9 million (Q1 2020), -$222.5 million (Q4 2019), and -$71.2 million (Q1 2019), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Grifols | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | -74.92 Mn |
| Dec 31, 2019 | -222.47 Mn |
| Mar 31, 2019 | -71.16 Mn |
| Dec 31, 2018 | -194.59 Mn |
| Mar 31, 2018 | -66.30 Mn |
| Dec 31, 2017 | -214.16 Mn |
| Mar 31, 2017 | -63.04 Mn |
| Dec 31, 2016 | 0.00 |
| Sep 30, 2016 | 0.00 |
| Dec 31, 2015 | 1.04 Bn |
| Jun 30, 2015 | 0.00 |
| Mar 31, 2015 | 0.00 |
| Jun 30, 2012 | 1.01 Mn |
| Mar 31, 2012 | 135,065.50 |
| Sep 30, 2011 | 10.72 Mn |
| Jun 30, 2011 | -430,948.46 |
| Mar 31, 2011 | 422,558.32 |
| Sep 30, 2010 | 570,742.50 |